Tarsus Pharmaceuticals Inc. closed an upsized $134.8 million public offering this month.The Irvine-based biopharmaceutical ...

A common eyelid disease caused by infestation with tiny parasitic mites that live in hair follicles now has its first approved treatment in the US. Tarsus Pharmaceuticals' Xdemvy (lotilaner) has ...

Tarsus Pharmaceuticals' Xdemvy, the first approved treatment for Demodex blepharitis, generated $180M in 2024 sales, with significant growth potential in a large addressable market. Analysts ...

Tarsus Pharmaceuticals Inc. (Nasdaq: TARS), ranked No. 1 in the midsize category, has become a standout in OC’s biotech ...

The treatment of blepharitis focuses on alleviating symptoms, addressing underlying causes, and preventing complications. [iStockphotos] Blepharitis is a common chronic condition that affects the ...

Eyelash extensions are wildly popular, but are they safe? Kimberly Orr, an optometrist from Triad Eye Associates, sets the ...